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EpidermisHyperbilirubinemia continues to pose a signiﬁcant and common problem in the newborn period. Exposure of the
brain to high levels of unconjugated bilirubin leads to acute bilirubin encephalopathy and kernicterus, especially
in preterm infants. Given the shared embryological origin of the skin (epidermis) and brain, we hypothesized
that cutaneous binding of unconjugated bilirubin to skin (i.e., jaundice) might protect the immature brain. Sup-
port for this hypothesis requires direct quantiﬁcation of binding of unconjugated bilirubin to cutaneous struc-
tures. Bilirubin binding was tested using a series of in vitro experiments wherein newborn skin and vernix
caseosawere exposed to physiologically-relevant solutions of bilirubin. Tissue bindingwas assessed spectropho-
tometrically and via bilirubin autoﬂuorescence. Study ﬁndings indicate the following: (1) unconjugated bilirubin
binds quickly and avidly to thin ﬁlms of vernix caseosa; (2) bilirubin binds to human epidermis in vitro via a
mechanism involving dermal diffusion; (3) unconjugated bilirubin localizes to the dermis and epidermis as
shown by autoﬂuorescence; and (4) topical application of vernix caseosa to the epidermis augments bilirubin
binding; i.e., increases jaundice. These ﬁndings are consistent with a physiological neuroprotective role for the
skin in shielding the immature brain from high levels of unconjugated bilirubin. New therapies based on these
results are envisioned with the goal of increasing cutaneous bilirubin binding (jaundice) thereby protecting the
developing brain and facilitating bilirubin excretion with phototherapy.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Bilirubin encephalopathy results when unconjugated bilirubin ex-
ceeds the binding capacity of serum albumin and crosses the blood–
brain barrier leading to irreversible neuronal injury following binding
to central brain structures.1–4 Newborn jaundice results when unconju-
gated bilirubin binds to skin in sufﬁcient amount to cause yellow
discoloration.5–8 Evidence that jaundice is the result of tissue staining
is easily seen by the fact that blanching of the skin surface after short
term cutaneous pressure eliminates blood perfusion and reveals the
yellow color of the skin. Hypothetically, newborn jaundice is a physio-
logical mechanism protecting the brain from hyperbilirubinemia by a
‘sump’ mechanism wherein serum bilirubin crosses the epidermal–
dermal junction to bind reversibly to epidermal structures.
In this view, the binding of unconjugated bilirubin to the skin is a
physiological neuroprotective mechanism shielding the immature
brain from the harmful effects of bilirubin binding. Cutaneous bilirubin
binding has the additional beneﬁt of holding bilirubin in a superﬁcial
position at the body surface where phototherapy (circa 480–490 nm)
can potentiate conversion of bilirubin to a water soluble form for uri-
nary elimination. The following experiments were designed to test thenati Children's HospitalMedical
innati, OH 45244, United States.
Inc. This is an open access article unhypotheses that (1) bilirubin binds in vitro to newborn skin and vernix
caseosa (VC) and (2) cutaneous binding can be enhanced by application
of topical skin products such as vernix.
Design/Methods
Afﬁnity of VC for bilirubin was demonstrated by exposing uniform
thin ﬁlms of VC to unconjugated bilirubin (20mg/dL) over a 1-h period.
In a separate experiment, full-thickness foreskin specimens with or
without VC overlay were placed dermis-side down and exposed to un-
conjugated bilirubin (20 mg/dL) through a semi-permeable polycar-
bonate membrane for 120 min at 37°C. Bilirubin was quantiﬁed by
(1) using the b-scale value from a Hunter L-a-b color space measure-
ment wherein a shift toward yellow indicates an increase in bilirubin
content and (2) optical density (OD) determination at 485-nm using a
hand-held Ocean Optics USB200 spectrometer.
Results
Afﬁnity of Native Vernix for Unconjugated Bilirubin
Native vernixwas spread onto plastic slides at a ﬁlm thickness of ap-
proximately 300 microns using an Accugate spreader and placed in a
staining chamber so that the bottom half of the ﬁlm was submerged
in a solution of unconjugated bilirubin (20 mg/dL). After 5, 15, 30, 60,der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Time dependent binding of unconjugated bilirubin to native vernix caseosa. Standardized thin ﬁlms of vernix caseosawere applied to glass slides and exposed to bilirubin solutions
for times varying from 0 to 120min. Avid time dependent binding of bilirubin was evident. This phenomenon is consistent with the common clinical observation ofmeconium staining of
vernix due to bile pigments.
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ddH2O to remove any adherent solution, and photographed to yield
the images in Fig. 1. Results indicated a time dependent increase in bil-
irubin staining. The slides were then placed under aWild dissectingmi-
croscope and re-photographed at 6.4× magniﬁcation with a Nikon
Cool-pix 4500 digital camera. The images were converted to Hunter L-
a-b mode in Adobe Photoshop and scored on the b-scale (blue-yellow).
A greater b-scale value indicates that the image contains more yellow,
i.e., contains more bilirubin. These slides were also analyzed for
b-scale determination using a Minolta Chromameter with similar re-
sults (data not shown). The graph in Fig. 2 provides quantitation for
the visual image depicted in Fig. 1.Fig. 2.Quantiﬁcation of bilirubin binding to human vernix. The slides shown in Fig. 1 were
rinsed in ddH2O and photographed to show a time-dependent increase in bilirubin staining.
Images were examined by Hunter L-a-b color space analysis and scored on the b-scale
(blue-yellow). A greater b-scale value indicates that the image contains more yellow,
i.e., contains more bilirubin.Free (Unconjugated) Bilirubin Will Bind to Human Skin (Epidermis)
In Vitro
Freshly harvested human neonatal foreskin was debrided of subcu-
taneous fat and cut into circular pieces using a 3-mm diameter dispos-
able biopsy punch. Each whole skin specimen was placed dermis-side
down onto a polycarbonatemembrane that comprised the ﬂoor of a Co-
star Transwell® insert. The tissue culture platewellswere partially ﬁlled
with a bilirubin solution (20 mg/dL) prepared as described by Clark
et al.5 and the inserts placed into the wells. In these experiments,
the dermis did not directly contact the bilirubin solution insofar as
the skin specimens rested on the upper side of the polycarbonateFig. 3. Binding of free (unconjugated) bilirubin to newborn human skin in vitro. Bilirubin
uptake was measured using neonatal foreskin explants. Exposure occurred from the
dermal side and was identiﬁed by imaging the epidermis using a hand-held USB200
spectrometer focusing on the 460–520 nm range.
Fig. 4. Bilirubin binding by neonatal foreskin explants. Following the same experimental
protocol as in Fig. 3, bilirubin uptake was quantiﬁed by Hunter b-scale measurement
using a Konica–Minolta Chromameter at 480–490 nm.
Fig. 6. Augmentation of bilirubin binding to human neonatal skin by topical application of
vernix caseosa. Fresh human foreskins were debrided of subQ fat, cut in half and treated
topically with vernix (50mg). Paired controls were untreated. Circular 3-mm punch biopsies
were transferred to Transwell® inserts and exposed to a bilirubin solution (20 mg/dL). After
120min at 37°C, the specimenswere scannedwith ahand-heldUSB200 spectrometer. Vernix
pretreatment augmented bilirubin binding as measured spectrophotometrically (Fig. 5).
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membranes. Diffusion occurred across the width of the membrane.
After 120 min at 37°C, the specimens were removed from the inserts.
Speciﬁc bilirubin uptake was identiﬁed by the use of a hand-held
USB200 spectrometer focused on the 480–490 nm range (Fig. 3) and
quantiﬁed more generally by Hunter b-scale measurement using a
Minolta Chromameter (Fig. 4).Localization of Unconjugated Bilirubin Within Excised Skin
Bilirubin localization was determined by confocal microscopy.
Brieﬂy, skin specimens were exposed to bilirubin as described
above and then placed in neutral buffered formalin and prepared
for parafﬁn sectioning. Following sectioning, the specimens were
stained with the ﬂuorescent nuclear stain, Draq-5, for contrast and
examined using a Zeiss LSM 510 laser scanning confocal microscope
to localize bilirubin by autoﬂuorescence. The sections were exposed
to laser excitation at 488 nm, 543 nm and 633 nm. Using a 560 nm–
615 nm band pass ﬁlter, bilirubin was visualized by autoﬂuores-
cence (Fig. 5). Of importance, the bilirubin not only was visualized
in dermis (possibly bound to high afﬁnity sites in collagen) but
also in the epidermis, particularly at the junction of the MalphighianFig. 5. Localization of unconjugated bilirubinwithin excisednewborn skin. Skin specimens expo
nuclear stain, Draq-5 for contrast and examined using a Zeiss LSM 510 laser scanning confocal
unexposed control skin while panel b depicts prominent bilirubin autoﬂuorescence (arrows) in botlayer and stratum corneum layer of the epidermis. This is precisely
the localization, which would be preferred for presentation to blue
light phototherapy.Sequestration of Bilirubin in Skin by Native Vernix Following
Topical Application
Freshly harvested human foreskins were debrided of subcutaneous
fat and cut in half. One half of each foreskin was treated topically with
a small amount of native vernix (approximately 50 mg). Native vernix
was scraped from healthy term newborns skin surface immediately
after birth by using a wooden spatula. Circular piece specimens were
cut using a 3-mm diameter disposable biopsy punch, transferred to Co-
star Transwell® inserts and exposed to a bilirubin solution as described
above. Each insert contained two skin specimens that were pair-
matched to be from the same donor. One of the specimens was
vernix-treated; the other one was untreated and served as a control.
After 120 min at 37°C, the specimens were removed from the inserts
and scanned with a hand-held USB200 spectrometer. Vernix treatment
signiﬁcantly augmented bilirubin binding as measured spectrophoto-
metrically (N= 5) (Fig. 6).sed to bilirubin solutions (20mg/dL)were ﬁxed, sectioned and stainedwith theﬂuorescent
microscope to localize bilirubin by autoﬂuorescence (see Design/Methods). Panel a depicts
h the dermis and superﬁcial epidermis.
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These experiments indicate the following: (1) unconjugated biliru-
bin binds quickly and avidly to thin ﬁlms of vernix caseosa (Figs. 1
and 2); (2) bilirubin binds to human epidermis in vitro via amechanism
involving dermal diffusion (Figs. 3 and 4); (3) unconjugated bilirubin
localizes to the dermis and epidermis as shown by autoﬂuorescence
(Fig. 5a–b); and (4) topical application of vernix caseosa to the epider-
mis augments bilirubin binding; i.e., increases jaundice (Fig. 6).Discussion
Neonatal hyperbilirubinemia is one of the most common problems
encountered in newborn care. About 60% of newborn infants in the US
are jaundiced in the immediate newborn period.9 Despite routine
monitoring and effective methods of treatment such as phototherapy,
elevated levels of unconjugated bilirubin still occur and are associated
with acute bilirubin encephalopathy as well as permanent neurologic
sequelae (kernicterus).10–13
The production of bilirubin from heme following destruction of
erythrocytes bymacrophages in the spleen andbonemarrow iswell un-
derstood. Unconjugated (free) bilirubin partially bound to serum albu-
min is transferred to the liver where it is conjugated with glucoronic
acid and excreted in the bile and/or urine in the form of stercobilin
and urobilinogen. The pigmented appearance of stool and urine is due
to these bilirubin breakdown products. Prenatally, the placenta rather
than the fetal liver effectively handles unconjugated bilirubin.
Hyperbilirubinemia is common in the neonate and the detection of
jaundice is an essential part of the normal newborn examination.13–15 Pre-
term infants aremore prone to developproblemswith hyperbilirubinemia
secondary to easier passage of free bilirubin across the blood–brain bar-
rier with irreversible binding to central brain structures leading to de-
vastating neurodevelopmental consequences, including kernicterus,
deafness and cognitive disorders if bilirubin levels are not monitored
and treated.4,9,14,16 Exposure of jaundiced skin to sunlight and/or
blue light (phototherapy) results in photoconjugation of cutaneous
bilirubin and production of a soluble bilirubin product which can be
excreted in the urine. Access to phototherapy is critical for treatment
of jaundiced infants but is often limited in home environments and
developing countries.
Embryologically, the binding of bilirubin to epidermis, is similar to
the binding of bilirubin to the brain and is consistentwith the shared ec-
todermal origin of epidermis and brain.17 This common origin supports
the concept that the epidermal–dermal junction has similarities to the
blood–brain barrier18,19 insofar as unconjugated bilirubin must cross
these complex interfaces prior to binding to tissue structures. For un-
known reasons, neonatal jaundice is ﬁrst apparent over the face and is
secondary to binding of bilirubin speciﬁcally to epidermal lipids or lipo-
protein components. Teleologically, this results in more efﬁcacious
natural treatment of jaundiced infants due to exposure to sunlight.
The possibility that neonatal jaundice; i.e., binding of bilirubin to cutane-
ousmolecular components is therapeuticdue to sequestrationof potential-
ly toxic bilirubin in a strategic location accessible to photo-conjugation by
natural means (sunlight) has not been previously considered.Unconjugated bilirubin bindswithhigh afﬁnity to themultifunctional
fetal skin cream vernix caseosa as well as to human newborn epidermis.
Topical application of vernix increases bilirubin binding to human
epidermis in vitro. These results support the development of novel topi-
cal therapies such as ‘synthetic vernix’ for augmenting efﬁcacy of photo-
therapy and treating neonatal hyperbilirubinemia. The development and
validation of methods (topical vernix equavalents) to accentuate the se-
questration of bilirubin in the epidermis in order to potentiate standard
phototherapy would be a major and innovative approach in the treat-
ment of neonatal hyperbilirubinemia. Such topical therapies could be
combined with judicious neonatal massage and emollient therapy.20,21
Preterm infants with immature blood–brain barrier and the highest
risk for bilirubin encephalopathy would be most beneﬁted from this
proposed therapy. Overall these ﬁndings are consistent with the core
measures for neuroprotection in the Neonatal Integrative Developmental
Care Model.22
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